Skip to main content
SpringerLink
Log in

Calciumantagonisten zur Überwindung von P-Glykoprotein-bedingter „Multidrug Resistance“ von Krebserkrankungen

  • Chapter
Calciumantagonisten

  • 25 Accesses

Zusammenfassung

Resistenz von Krebszellen gegen zytotoxische Chemotherapie ist eine wichtige Ursache für die oft unbefriedigenden Behandlungsergebnisse bei fortgeschrittenen Krebserkrankungen. Dabei sind Krebserkrankungen häufig nicht nur resistent gegen jene Substanzen, welche bereits verwendet wurden, sondern auch gegen eine Reihe anderer strukturell und funktionell unterschiedlicher Zytostatika. Ein ähnliches Verhalten zeigen Krebszellen bei einer bestimmten Form von experimenteller Chemotherapieresistenz, welche „multidrug resistance“ oder MDR genannt wird. Aufgrund dieser Ähnlichkeit mit klinischer Chemotherapieresistenz hat MDR großes Interesse ausgelöst. Wir wissen heute, daß MDR durch verschiedene molekulare Mechanismen verursacht werden kann. Dazu gehören erhöhte Expression von Transportproteinen wie P-Glykoprotein (Pgp) oder MRP („Multidrug-Resistance-Protein”), erhöhte Aktivität des Glutathion-Redox-Zyklus, oder verminderte Aktivität von Topoisomerase II α (1, 2). Derzeit am ausführlichsten erforscht ist die Pgp-bedingte MDR (Pgp-MDR). Dieser Beitrag ist ein Versuch, den derzeitigen Wissenstand über Pgp-MDR zusammenzufassen, mit Schwerpunkt auf Überwindung von Pgp-MDR durch Calciumantagonisten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Moscow JA, Cowan KH (1988) Multidrug resistance. J Natl Cancer Inst 80: 14–20

    Article  PubMed  CAS  Google Scholar 

  2. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427

    Article  PubMed  CAS  Google Scholar 

  3. Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Playsic M, Chou J, Drumm M, Iannuzzi M, Collins F, Tsui L (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066–1073

    Article  PubMed  CAS  Google Scholar 

  4. Foote SJ, Thompson JK, Cowman AF, Kemp DJ (1989) Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 57; 921–930

    Article  PubMed  CAS  Google Scholar 

  5. Goldstein U, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116–124

    Article  PubMed  CAS  Google Scholar 

  6. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis L, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson IB (1990) Quantitative analysis of MDR1 (multidrug resistance gene) expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160–7164

    Article  PubMed  CAS  Google Scholar 

  7. Arceci RJ (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81: 2215–2222

    PubMed  CAS  Google Scholar 

  8. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Ride HPJ, Berns AJM, Borst P (1994) Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491–502

    Article  PubMed  CAS  Google Scholar 

  9. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972

    PubMed  CAS  Google Scholar 

  10. Kessel D, Wilberding C (1985) Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res 45: 1687–1691

    PubMed  CAS  Google Scholar 

  11. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–199

    PubMed  CAS  Google Scholar 

  12. Martin SK, Oduola AMJ, Milhous WK (1987) Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235: 899–901

    Article  PubMed  CAS  Google Scholar 

  13. Philip PA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K, Carmichael J, Idle JR, Harris AL (1992) A phase I study on the reversal of multidrug resistance ( MDR) in vivo: Nifedipine plus etoposide. Br J Cancer 65: 267–270

    Article  PubMed  CAS  Google Scholar 

  14. Van Kalken CK, van der Hoeven JJM, de Jong J, Giaccone G, Schuurhuis GJ, Maessen PA, Blokhuis WMD, van der Vijgh WJF, Pinedo HM (1991) Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer 27: 739–744

    Article  PubMed  Google Scholar 

  15. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641–647

    PubMed  CAS  Google Scholar 

  16. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP (1991) Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78: 44–50

    PubMed  CAS  Google Scholar 

  17. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-gycloprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17–24

    PubMed  CAS  Google Scholar 

  18. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE (1991) Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83: 105–110

    Article  PubMed  CAS  Google Scholar 

  19. Sikic BI (1993) Modulation of multidrug resistance: At the threshold. J Clin Oncol 11: 1629 1635

    Google Scholar 

  20. Lehnert M (1994) Reversal of P-glycoprotein-associated multidrug resistance: From bench to bedside. Onkologie 17: 8–15

    Article  Google Scholar 

  21. Mickisch GH, Kössig J, Keilhauer G, Schlick E, Tschada RK, Alken PM (1990) Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 50: 3670–3674

    PubMed  CAS  Google Scholar 

  22. Pirker R, Keilhauer G, Raschak M, Lechner C, Ludwig H (1990) Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer 45: 916919

    Article  PubMed  CAS  Google Scholar 

  23. Echizen H, Brecht T, Niedergesaess S, Vogelsang B, Eichelbaum M (1985) The effect of dextro-levo- and racemic verapamil on atrio-ventricular conduction in humans. Am Heart J 109: 210–217

    Article  PubMed  CAS  Google Scholar 

  24. Bisset D, Kerr DJ, Cassidy J, Meredith P, Traugott U, Kaye SB (1991) Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64: 1168–1171

    Article  Google Scholar 

  25. Bates S, Wilson W, Fojo T, Wittes R, Bryant G, Chabner B (1994) R-verapamil reverses drug resistance in some relapsed lymphoma patients. Anti-Cancer Drugs 5 (Suppl 1 ): 165 (Abstr)

    Google Scholar 

  26. Thürlimann B, Mross K, Greiner J, Kröger N, Schuller J, Schernhammer E, Schumacher K, Gastl G, Hartlapp J, Kupper H, Lehnert M (1995) Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol (in press)

    Google Scholar 

  27. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB (1986) The effect of verapamil on the pharmacokinetics of adriamycin. Br J Cancer 18: 239–242

    CAS  Google Scholar 

  28. Mross K, Hamm K, Hossfeld DK (1993) Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 31: 369–375

    Article  PubMed  CAS  Google Scholar 

  29. Scheithauer W, Schenk T, Czejka M (1993) Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer 68: 8–9

    Article  PubMed  CAS  Google Scholar 

  30. Lum BL, Kraubisch S, Yahanda AM, Adler KM, Jew L, Ehsan NN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635–1642

    PubMed  CAS  Google Scholar 

  31. Sikic BI (1994) Pharmacokinetic effects of modulation of multidrug resistance. Anti-Cancer Drugs 5 (Suppl 1 ): 162 (Abstr)

    Google Scholar 

  32. Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Löwenberg B, Nooter K (1992) Modulation of multidrug-resistant multiple myeloma with cyclosporin. Lancet 340: 255–259

    Article  PubMed  CAS  Google Scholar 

  33. Lehnert M, Kunke K, Roe D, Dorr R, Dalton WS, Salmon SE (1990) In vivo concentration of serum proteins significantly inhibits reversal of P-glycoprotein-mediated drug resistance by some chemosensitizers. Proc Am Assoc Cancer Res 31: 2250 (Abstr)

    Google Scholar 

  34. Lehnert M, Emerson S, Dalton WS, de Giuli R, Salmon SE (1993) In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated taxol resistance. Monogr Natl Cancer Inst 15: 63–67

    PubMed  Google Scholar 

  35. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE (1991) Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 77: 348–354

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Lehnert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin III, Medizinische Universitätsklinik, Bergheimer Straße 58, 69115, Heidelberg, Deutschland

    Wolfgang Kübler

  2. Institut für Medizinische Physik und Biophysik, Harrachgasse 21, A-8010, Graz, Österreich

    Helmut A. Tritthart

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt

About this chapter

Cite this chapter

Lehnert, M. (1996). Calciumantagonisten zur Überwindung von P-Glykoprotein-bedingter „Multidrug Resistance“ von Krebserkrankungen. In: Kübler, W., Tritthart, H.A. (eds) Calciumantagonisten. Steinkopff. https://doi.org/10.1007/978-3-642-93678-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93678-4_17

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-642-93679-1

  • Online ISBN: 978-3-642-93678-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation